Brainsway Ltd

BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference

Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants

BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights